Biotinylated GRA1 recombinant protein as well as preparation method and application thereof
By constructing GRA1 recombinant proteins with Avi tags and using biofilm interference technology, the problem that existing Toxoplasma gondii detection methods cannot distinguish positive and negative serums is solved, and rapid and accurate detection of Toxoplasma gondii infection in mice is achieved, providing new detection ideas and clinical testing plans.
Patent Information
- Application Number
- CN202411168339.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-06
AI Technical Summary
Existing Toxoplasma test methods cannot effectively distinguish positive and negative serums, and lack rapid and accurate diagnostic tools, especially in animal infections.
By constructing GRA1 recombinant proteins with Avi tags, using biofilm interference technology (BLI) to combine biotinylated labels, a serological detection method based on biofilm interference is established, and the biotinylated GRA1 recombinant protein is used as a diagnostic antigen to achieve Rapid and accurate detection of Toxoplasma infection in mice.
This method can quickly and accurately distinguish between positive and negative serum in mice, provide reference for clinical testing protocols for animal Toxoplasma infection, and improve the accuracy and efficiency of the detection.
Smart Images

Figure CN119080904A_ABST
Abstract
Description
Technical Field
[0001] The embodiments of the present invention relate to the field of biotechnology, and in particular to a biotinylated GRA1 recombinant protein and a preparation method and application thereof. Background Art
[0002] Toxoplasma gondii is an important zoonotic parasite that can infect almost all warm-blooded animals, including humans, and specifically invades the host's nucleated cells. About one-third of the world's population is positive for Toxoplasma infection. The positive rate of serum antibodies in the Chinese population is 5% to 10%; the infection rate of Toxoplasma gondii in cats is relatively high, about 24.5%. In addition to causing economic losses to the breeding industry, livestock and poultry infections have also become a potential risk factor for human infection. Infection in people with normal immune function is often latent and has no obvious clinical symptoms, but infection in individuals with immune deficiency (such as patients with malignant tumors, AIDS patients or organ transplant recipients, etc.) will lead to serious consequences and even death. No effective vaccine has been developed for Toxoplasma infection so far. At present, the disease is still mainly treated with Western medicine. Drugs for the treatment of acute toxoplasmosis include sulfadiazine, pyrimethamine, spiramycin, etc., but these drugs can only kill some trophozoites, inhibit the reproduction of the parasites, and improve symptoms. They cannot effectively prevent the formation of cysts, let alone kill the parasites in the cysts, and may also cause serious side effects.
[0003] At present, there are many methods for detecting Toxoplasma gondii. Serological detection is the most commonly used detection method. It is usually to detect IgG, IgM and IgA antibodies in serum through parasite antigens. Therefore, detecting antigens is the core of serological detection methods. The dense granule proteins of Toxoplasma gondii can affect the immune response of host cells, thereby helping the parasites avoid being recognized and eliminated by the host's immune system. These proteins may also intervene in regulating the cycle of host cells, as well as the transport and localization of the parasite's own proteins. More than 70 dense granule proteins have been reported, among which GRA1 protein is the first dense granule protein discovered and named through immunogenicity screening. GRA1 is a completely soluble protein. After being secreted by dense granules, it is transported to the lumen of the parasite vacuole and exists there in a soluble form. It can be expressed in both the tachyzoite and bradyzoite stages of Toxoplasma gondii. Studies have shown that GRA1 plays an important role in the diagnosis and treatment of Toxoplasma gondii and can be used as a potential candidate molecule for anti-Toxoplasma vaccines or diagnostic reagents.
[0004] Biofilm interferometry works by shining white light onto a fiber-optic biosensor and then measuring the interference between the light reflected from the two layers (reference layer and biolayer). Binding of molecules to the biosensor surface generates a real-time signal due to changes in the wavelength of the reflected light.
[0005] Some studies have immobilized biotinylated synthetic sialoglycans or sialoglycans on the surface of streptavidin-coated biosensors, and used biolayer interferometry (BLI) to analyze and quantify influenza A virus (IAV)-receptor interactions in real time (de Vries et al., 2022). Bajardi-Taccioli et al. developed a new BLI-based FcγRIIa binding detection method. The analysis measures the associated binding reaction and uses parallel line analysis to calculate the binding potency of the sample relative to the standard. This method overcomes the interference of aggregates present in the sample, distinguishes different Fc glycosylation patterns, and is stable. It can be used for sample characterization, drug release, and stability testing (Bajardi-Taccioli et al., 2020). At present, there are no reports on the application of biofilm interferometry in serological detection of parasites. Summary of the invention
[0006] To this end, the embodiments of the present invention provide a biotinylated GRA1 recombinant protein and a preparation method and application thereof. The present invention uses a prokaryotic expression vector to express a GRA1 recombinant protein with an Avi tag in vitro and successfully biotinylate it, and further uses the biotinylated GRA1 recombinant protein as a diagnostic antigen to establish a serological detection method based on biomembrane interferometry (BLI). The method can quickly and accurately distinguish between positive and negative serum in mice, providing a reference for clinical detection programs for Toxoplasma gondii infection in animals.
[0007] In order to achieve the above purpose, the embodiment of the present invention provides the following technical solutions:
[0008] According to a first aspect of an embodiment of the present invention, the present invention provides a method for preparing a biotinylated GRA1 recombinant protein, comprising the following steps:
[0009] (1) constructing a GRA1 recombinant protein, wherein the GRA1 recombinant protein has an amino acid sequence as shown in SEQ ID NO: 1;
[0010] (2) The GRA1 recombinant protein is biotinylated in the presence of BirA, and dialyzed to obtain the biotinylated GRA1 recombinant protein.
[0011] Furthermore, the construction of the GRA1 recombinant protein specifically includes:
[0012] (1-1) extracting RNA of Toxoplasma gondii RH strain and reversely transcribing it into cDNA;
[0013] (1-2) using cDNA as a template to amplify the GRA1 gene, recovering and purifying the PCR product;
[0014] (1-3) The purified PCR product was connected to the pET-His-MCS-Avi vector through the NdeⅠ and NotⅠ restriction sites, transformed into E. coli competent cells, and single colonies with successful cloning were picked out by ampicillin resistance, and the recombinant plasmid was extracted and named pET-His-MCS-Avi-GRA1;
[0015] (1-4) Expression and purification of GRA1 recombinant protein
[0016] The recombinant plasmid pET-His-MCS-Avi-GRA1 was transformed into Escherichia coli competent cells BL21 (DE3) and induced to express in LB culture medium containing ampicillin and IPTG. The bacteria were collected by centrifugation, ultrasonically disrupted, and the supernatant was separated and precipitated. The target protein was purified by Ni-NTA column and identified by SDS-PAGE and Western blot.
[0017] Further, in step (1-2),
[0018] The primers for amplifying the GRA1 gene include a forward primer and a reverse primer, wherein the forward primer has a nucleotide sequence as shown in SEQ ID NO: 2, and the reverse primer has a nucleotide sequence as shown in SEQ ID NO: 3. The present invention finds that the use of the forward primer and reverse primer can ensure the accuracy of the recombinant plasmid sequence.
[0019] Further, in step (1-4),
[0020] The induction expression conditions are: temperature 16° C., rotation speed 220 rpm, time 16 h, ampicillin concentration 100 mg / mL, IPTG concentration 0.1 mM.
[0021] Furthermore, in step (2),
[0022] The biotinylation labeling reaction system is: Biotin Ligase Buffer A 10X, Biotin Ligase Buffer B 10X, BirA 100X, GRA1 recombinant protein, ddH 2 O, reaction conditions: 30°C, 1h.
[0023] The dialysis conditions are as follows: using phosphate buffered saline (PBS) with a pH of 7.0 as the dialysis fluid, 2 L of dialysis fluid each time, 4° C., dialysis for 1 h, and 3 dialysis sessions in total.
[0024] According to a second aspect of the embodiments of the present invention, the present invention provides a biotinylated GRA1 recombinant protein, which is prepared by the method described in any one of the above items.
[0025] According to a third aspect of the embodiments of the present invention, the present invention provides a use of the biotinylated GRA1 recombinant protein as described above in the detection of Toxoplasma gondii-specific antibodies in serum samples.
[0026] According to a fourth aspect of the embodiments of the present invention, the present invention provides a BLI detection method for identifying mouse positive serum based on the biotinylated GRA1 recombinant protein as described above, comprising the following steps:
[0027] (1) Sensor curing: After pre-wetting the streptavidin sensor in PBS buffer for 60 seconds, immerse it in a biotinylated GRA1 recombinant protein solution diluted in PBS and incubate it at 30°C for 300 seconds. Meanwhile, record the real-time binding signal on the sensor surface. When the signal reaches saturation, terminate the binding and the sensor is cured. Store it at 4°C for future use.
[0028] (2) Baseline 1: Immerse the cured sensor in serum dilution and equilibrate at 30 °C for 120 s;
[0029] (3) Loading 1: Immerse the equilibrated sensor in the serum sample to be tested diluted with serum diluent and incubate at 30°C for 300 s;
[0030] (4) Wash: Immerse the serum-bound sensor in serum diluent and incubate at 30°C for 60 seconds to wash away nonspecifically bound serum;
[0031] (5) Loading 2: Immerse the washed sensor in HRP-labeled goat anti-mouse secondary antibody diluted in serum diluent and incubate at 30°C for 180s;
[0032] (6) Wash: Immerse the sensor bound to the secondary antibody in serum dilution solution and incubate at 30°C for 60 seconds to wash the non-specifically bound secondary antibody;
[0033] (7) Association: The washed sensor was immersed in DAB diluted with serum diluent and incubated at 30°C for 180s to undergo a signal amplification reaction and obtain a binding signal value. When the binding signal value was greater than 0.186nm, the sample was positive; when the binding signal value was less than 0.168nm, the sample was negative; when the binding signal value was between 0.168-0.186nm, it was determined to be a suspected false positive;
[0034] (8) Dissociation: Immerse the sensor in serum dilution to terminate the signal emission reaction.
[0035] Furthermore, the serum diluent is PBS+0.02% Tween+0.1% BSA;
[0036] The dilution ratio of serum samples was 1:100;
[0037] The dilution ratio of HRP-labeled goat anti-mouse secondary antibody was 1:1000;
[0038] The dilution ratio of DAB was 1:200.
[0039] Studies have shown that the present invention uses PBS+0.02% Tween20+0.1% BSA as a serum diluent to reduce serum nonspecificity to the greatest extent, thereby improving the accuracy of detection.
[0040] The embodiments of the present invention have the following advantages:
[0041] In order to establish a BLI detection method for chronic infection of Toxoplasma gondii in mice, the prokaryotic expression vector pET-His-MCS-Avi-GRA1 of GRA1 recombinant protein with His tag and Avi tag was first constructed, and the expression conditions were optimized to express and purify the GRA1 recombinant protein with double tags. The biotin kit was further used to specifically label the Avi tag with biotin. The reaction conditions were milder, the operation was simpler, and the activity of the labeled protein was less affected. Western blot results showed that the biotinylated GRA1 recombinant protein was successfully obtained, and the biotinylation efficiency was high.
[0042] The present invention prepares a sensor with biotinylated GRA1 recombinant protein, and preliminarily establishes a detection method of biomembrane interferometry (BLI) with biotinylated GRA1 as a diagnostic antigen, determines that the optimal dilution ratio of the detected serum sample is 1:100, the optimal dilution ratio of the HRP-labeled goat anti-mouse secondary antibody is 1:1000, and the optimal dilution ratio of DAB is 1:200. The established detection method can quickly and accurately distinguish between mouse positive serum and negative serum. The research results provide new ideas for Toxoplasma serological detection and provide a reference for the clinical detection program of Toxoplasma infection in animals. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] In order to more clearly illustrate the implementation methods of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for the implementation methods or the description of the prior art. Obviously, the drawings in the following description are only exemplary, and for ordinary technicians in this field, other implementation drawings can be derived from the provided drawings without creative work.
[0044] Figure 1 Amplification of the GRA1 target gene provided by the present invention;
[0045] Figure 2This is the double enzyme digestion verification of the target fragment and the vector provided by the present invention. A: The band in lane 1 is irrelevant to this experiment, and lane 2 is the double enzyme digestion of the target fragment; B: double enzyme digestion of the pET-His-MCS-Avi vector;
[0046] Figure 3 Double enzyme digestion verification of the pET-His-MCS-Avi-GRA1 recombinant plasmid provided by the present invention;
[0047] Figure 4 This is the expression verification of pET-His-MCS-Avi-GRA1 provided by the present invention, A: SDS-PAGE verification; B: Western blot verification;
[0048] Figure 5 Purification verification of pET-His-MCS-Avi-GRA1 provided by the present invention, A: SDS-PAGE verification; B: Western blot verification;
[0049] Figure 6 Biotinylation verification of pET-His-MCS-Avi-GRA1 provided by the present invention, A: SDS-PAGE verification; B: Western blot verification of His tag antibody; C: Western blot verification of HRP-labeled streptavidin;
[0050] Figure 7 The sensor provided by the present invention and the GRA1 solidified real-time signal diagram;
[0051] Figure 8 A flow chart of the BLI detection scheme provided by the present invention;
[0052] Fig. 9 This is the sample concentration optimization result provided by the present invention. DETAILED DESCRIPTION
[0053] The following is a description of the implementation of the present invention by specific embodiments. People familiar with the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0054] Test materials
[0055] Plasmid, serum, streptavidin sensor
[0056] Plasmid: pET-His-MCS-Avi vector, purchased from Shanghai Bio-Tech Biotechnology Co., Ltd.;
[0057] The pET-28a-GRA1 plasmid was stored in the laboratory; the streptavidin (SA) sensor (18-5019) was purchased from Pall (China) Co., Ltd.
[0058] Serum: Mouse Toxoplasma-positive serum and mouse Toxoplasma-negative serum are stored in the laboratory.
[0059] Main reagents The reagents used in the test are shown in Table 1.
[0060] Table 1 Main reagents
[0061]
[0062]
[0063] Example 1
[0064] Preparation of biotinylated GRA1 recombinant protein
[0065] 1. Construction of recombinant plasmid
[0066] (1) Primer design and synthesis
[0067] The gene fragment of GRA1 was amplified on the sequence of the recombinant plasmid pET-28a-GRA1, and the primer sequences were designed as follows:
[0068] GRA1-NdeI-5: 5'-GGAATTCCATATGGTGCGTGTGAGCG-3' (SEQ ID NO: 2);
[0069] GRA1-NotI-3: 5'-AGTTTAGCGGCCGCCTCTCTCCTGTTAAG-3' (SEQ ID NO: 3).
[0070] (2) Amplification of the GRA1 gene fragment
[0071] Using the pET-28a-GRA1 plasmid as a template, PCR amplification of the GRA1 target fragment was performed, and the amplification system is shown in Table 2 below.
[0072] Table 2 PCR amplification components and systems
[0073]
[0074] PCR amplification conditions, 35 cycles are shown in Table 3.
[0075] Table 3 PCR reaction conditions
[0076]
[0077] (3) PCR product verification and purification recovery
[0078] The PCR product was verified by nucleic acid electrophoresis, and the target band was purified and recovered.
[0079] Electrophoresis verification: prepare 1% agarose gel, take 10 μL of 6× DNA Loading buffer and mix with PCR product, add all into the gel wells, set the electrophoresis instrument to 120V constant voltage, run for 30 minutes and then image the gel.
[0080] Purification and recovery: Use a blade to cut off the gel block with a single target band, cut it into pieces, put it into a centrifuge tube and weigh it. Gel recovery steps follow the Tiangen Gel Recovery Kit.
[0081] The recombinant plasmid pET-28a-GRA1 was used as a template to amplify the GRA1 target gene. A clear band was found at 573 bp by nucleic acid electrophoresis, which was consistent with the expected size ( Figure 1 ).
[0082] (4) Double digestion of pET-His-MCS-Avi vector and GRA1 target fragment
[0083] The vector and the recovered target fragment were double-digested using NotⅠ and NdeⅠ fast-cutting enzymes. The enzyme digestion system is shown in Table 4 below.
[0084] Table 4 Double restriction enzyme digestion system of vector and target fragment
[0085]
[0086] Add the reaction system into the PCR tube, shake and mix, centrifuge for a moment, and place in the PCR instrument for enzyme digestion at 37℃ for 15 minutes.
[0087] By nucleic acid electrophoresis verification, a clear band can be seen at 5799 bp for pET-His-MCS-Avi, which is consistent with the vector size, and a clear band can be seen at 573 bp for the target fragment, which is consistent with the size of GRA1 ( Figure 2 ).
[0088] (5) Ligation and transformation of enzyme digestion products
[0089] Ligation: The products after enzyme digestion are subjected to nucleic acid electrophoresis and purified and recovered, and the vector recovered by double enzyme digestion is connected with the target fragment. The connection system is shown in Table 5.
[0090] Table 5. Vector and target fragment connection system
[0091]
[0092] Add all the above reagents into the PCR tube, shake and mix, centrifuge for a moment, and place in a 16°C water bath to connect overnight.
[0093] The ligated product is transformed:
[0094] 5.1 Place the DH5α competent cells on ice, wait for 10 minutes to thaw, and pipette 50 μL of competent cells into a new 1.5 mL centrifuge tube;
[0095] 5.2 Take 3 μL of the ligation product, gently mix it with the competent cells, place it on ice for 30 minutes, heat shock it in a 42°C water bath for 90 seconds, and immediately cool it on ice for 2 minutes;
[0096] 5.3 Add 500 μL of antibiotic-free LB medium, incubate in a shaker at 220 rpm and 37°C for 1 hour, then take out;
[0097] 5. Centrifuge at 45000 rpm for 2 min, aspirate 300 μL of supernatant and discard, resuspend the remaining and drop it on an Amp (ampicillin) resistant culture dish, and spread the bacterial solution with a coating stick;
[0098] 5.5 Place in a 37°C incubator and culture overnight.
[0099] Use a pipette to pick up a single white, round colony on the culture dish and place it into 10 mL of ampicillin-resistant liquid culture medium. Incubate at 37°C, 220 rpm in a shaker for 12 hours until the bacterial solution becomes turbid. Extract the plasmid and send it to Shanghai Biotech for sequencing. For plasmid extraction steps, refer to the Novezan instructions.
[0100] The extracted plasmid was double-digested and verified by nucleic acid electrophoresis, showing two clear bands at 5799 bp and 573 bp, which was consistent with the expected results ( Figure 3 ).
[0101] 2. Expression and purification of pET-His-MCS-Avi-GRA1
[0102] (1) Expression of recombinant proteins
[0103] The correctly sequenced recombinant plasmid was transformed into BL21 (DE3) expression competent cells, and the operation steps were the same as the connection and transformation of the enzyme digestion product.
[0104] (2) Induce expression of pET-His-MCS-Avi-GRA1 in small amounts, the steps are as shown in Table 6.
[0105] Table 6 Small-scale induction expression steps
[0106]
[0107] (3) Polyacrylamide gel electrophoresis (SDS-PAGE)
[0108] 3.1 Prepare glue: Assemble glass plates, racks, and adhesive strips; check for leaks, and use filter paper to absorb water after the test; prepare glue according to the table below, mix well, and inject the lower layer of glue between the glass plates, press the glue with 75% anhydrous ethanol, drive out bubbles, and let it stand for 30 minutes to solidify; after solidification, pour out the anhydrous ethanol, use filter paper to absorb water, inject the upper layer of glue, insert a comb, and solidify for 30 minutes.
[0109] 3.2 SDS-PAGE electrophoresis: Align the gel plate and clamp it on the electrophoresis tank, inject 1× electrophoresis solution, check the tank for leakage, unplug the comb, add 10μL of sample to each well, set the constant voltage to 150V, and start electrophoresis for 60min; after the electrophoresis is over, turn off the instrument, remove the gel plate and pry it open gently, soak the protein gel in Coomassie Brilliant Blue, place it on a shaker for 30min, and stain it with ddH 2 After washing away the excess staining solution, soak the stained gel block in destaining solution until the protein gel becomes transparent, and then use a gel imaging instrument to image the gel.
[0110] (4) Western blotting to verify the expression of recombinant protein
[0111] 4.1 Primary antibody: Dilute His-tag mouse monoclonal antibody 1:2500 in 3% BSA blocking solution and incubate overnight at 4°C on a shaker.
[0112] 4.2 Wash the membrane: Wash the membrane with PBST for 10 min each time for up to 1 h.
[0113] 4.3 Secondary antibody: dilute the prepared AP-labeled secondary antibody 1:5000 and incubate at 37°C for 1 hour.
[0114] 4.4 Wash the membrane: Wash the membrane with PBST for 10 min each time for up to 1 h.
[0115] 4.5 Color development: BCIP and NBT are prepared in a 1:1 ratio, color development is carried out in a dark place, and scan the image.
[0116] Figure 4 A is the result of small-scale induction SDS-PAGE of recombinant protein, lane 1 is the uninduced whole bacteria, lane 2 is the uninduced supernatant, lane 3 is the uninduced precipitate, lane 4 is the IPTG-induced whole bacteria, lane 5 is the induced supernatant, and lane 6 is the induced precipitate. Figure 4 B is the Western blot result of the recombinant protein, lane 1 is the whole bacteria induced by IPTG, lane 2 is the induced supernatant, and lane 3 is the induced precipitate.
[0117] The results showed that all lanes had clear bands at 35 kDa, and the size was consistent with the theoretical value. It can be seen from the figure that the protein was expressed in both the supernatant and the precipitate, and the expression level in the supernatant was higher ( Figure 4 ).
[0118] (5) Purification of recombinant protein
[0119] Prepare two bottles of 500 mL liquid culture medium with the formula shown in Table 7 below.
[0120] Table 7 Liquid culture medium formula
[0121]
[0122]
[0123] The recombinant protein pET-His-MCS-Avi-GRA1 was purified in large quantities according to the conditions of small-scale induction exploration. The specific steps of protein purification are shown in Table 8. Figure 5 A is the result of imidazole elution at various concentrations during the protein purification process. Lane 1 is the flow-through, lane 2 is Ni beads, lane 3 is 20 mM imidazole, lane 4 is 60 mM imidazole, lane 5 is 100 mM imidazole, lanes 6 and 7 are 250 mM imidazole, and lane 8 is 500 mM imidazole. Figure 5 B is the Western blot verification result after purification.
[0124] The results showed that a large amount of protein could be eluted under 250 mM imidazole conditions, with an obvious band at 35 kDa, which was consistent with the expected protein size.
[0125] After sequencing, the amino acid sequence of the GRA1 recombinant protein is:
[0126] MGHHHHHHHHHHSSGHIEGRHMVRVSAIVGAAASVFVCLSAGAYAAEGGDNQSSAVSDRASLLGLLSGGTGQGLGIGESVELEMMGNTYRVERPTGNPDLLKIAIKTSDGSYSEVGNVNM EEVIDTMKSMQRDEEIFFRALNKGETVEEAIEDVAQAEGLNSEQTLQLEDAVSAVASVVQDEMNVIDDVQQLEKDKQQLKDDIGFLTGEREPRPQPVGGGGGLNDIFEAQKIEWHE(SEQ ID NO:1).
[0127] 3. Biotinylation and Dialysis of Recombinant Protein
[0128] (1) In vitro biotinylation labeling
[0129] For biotinylation of the recombinant protein, add the reaction volume in Table 9 below into the PCR tube, mix it by gently blowing with a pipette, and place it in a 30°C water bath to react for 1 hour. The recombinant protein with the Avi tag is biotinylated.
[0130] Table 9 Biotinylation reaction system
[0131]
[0132] (2) Biotin labeling verification
[0133] 2.1 Primary antibody: Add anti-His tag mouse monoclonal antibody to the blocking solution at a dilution of 1:5000 and incubate overnight at 4°C on a shaker.
[0134] 2.2 Wash the membrane: Wash the membrane with PBST for 6 times, 5 minutes each time.
[0135] 2.3 Secondary antibody: HRP-labeled anti-His tag goat anti-mouse IgG (H+L) and HRP-labeled streptavidin were diluted 5000-fold and 3000-fold with PBST-BSA, respectively, added to the incubation box, and incubated at 37°C for 1 h.
[0136] 2.4 Wash the membrane: Wash the membrane with PBST for 6 times, 5 minutes each time.
[0137] 2.5 Color development: Prepare ECL luminescent solution according to the instructions, expose and record the image on a chemiluminescent imager.
[0138] Western blot verification showed that the biotinylated protein and the unbiotinylated protein in the HRP-labeled anti-His tag goat anti-mouse IgG (H+L) group had a band at 35 kDa that was consistent with the size of the recombinant protein, but the HRP-labeled streptavidin group was only detected in the biotinylated protein sample, indicating that the GRA1 recombinant protein was successfully biotinylated. Figure 6 ).
[0139] (3) Dialysis of biotinylated recombinant protein
[0140] Phosphate buffered saline (PBS) with a pH of 7.0 was used as the dialysate, 2 L of the dialysate was used each time, the dialysate was dialyzed for 1 h at 4°C, and the dialysate was dialyzed 3 times in total.
[0141] Example 2
[0142] Establishment of a BLI method for diagnosing Toxoplasma gondii infection in mice based on biotinylated GRA1 recombinant protein
[0143] 1. Process of BLI detection method
[0144] 1.1 Sensor solidification: The streptavidin sensor was placed in PBS buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4, the same below) for 60 seconds, and then immersed in a 1 μM biotinylated GRA1 recombinant protein solution diluted in PBS, incubated at 30°C for 300 seconds, while recording the real-time binding signal on the sensor surface. When the signal reaches saturation, the binding is terminated, and the probe is solidified. It is then stored at 4°C for later use ( Figure 7 );
[0145] 1.2Baseline1: Immerse the cured sensor in serum diluent (PBS+0.02% Tween20+0.1% BSA) and equilibrate at 30°C for 120 seconds ( Figure 8 A);
[0146] 1.3 Loading 1: Immerse the balanced sensor in the diluted serum sample to be tested (the diluent is the serum diluent), and incubate at 30°C for 300s ( Figure 8 B);
[0147] 1.4Wash: Immerse the serum-bound sensor in serum diluent and incubate at 30°C for 60 seconds to wash away non-specifically bound serum (such as Figure 8 C);
[0148] 1.5 Loading 2: Immerse the washed sensor in diluted HRP-labeled goat anti-mouse secondary antibody (the diluent is serum diluent) and incubate at 30°C for 180s ( Figure 8 D)
[0149] 1.6Wash: Immerse the sensor bound to the secondary antibody in serum dilution solution, incubate at 30℃ for 60s, and wash the non-specifically bound secondary antibody ( Figure 8 E);
[0150] 1.7 Association: Immerse the washed sensor in diluted DAB (the diluent is serum diluent), incubate at 30℃ for 180s to amplify the signal ( Figure 8 F);
[0151] 1.8Dissociation: Immerse the sensor in serum dilution to stop the signal generation reaction ( Figure 8 G).
[0152] 2. Concentration optimization
[0153] The laboratory-preserved verified mouse Toxoplasma gondii positive sera (6 copies) and mouse negative sera were used as test samples (6 copies). The sample concentrations were diluted to 1:100 (volume ratio, the same below), 1:500, and 1:1000, respectively. The secondary antibody was HRP-labeled goat anti-mouse, diluted at 1:1000, and DAB was diluted at 1:200.
[0154] 3. Determination of critical value
[0155] According to the optimized conditions of serum samples determined above, the Toxoplasma gondii infection-negative mouse serum samples (12 samples) stored in the laboratory were tested by the BLI method, and the positive cutoff value of the method was determined according to the formula of Cut off cutoff value = average value (AV) + 3× standard deviation (SD).
[0156] Test results
[0157] (1) Serum sample concentration optimization results
[0158] like Fig. 9 As shown:
[0159] The average response of positive serum diluted 1:100 was 0.503nm, and the average response of negative serum diluted 1:100 was 0.129nm. The P / N value was 3.844, and the difference was extremely significant (p<0.001).
[0160] The average response of positive serum diluted 1:500 was 0.317nm, and the average response of negative serum diluted 1:500 was 0.160nm. The P / N value was 1.984, and the difference was not significant.
[0161] The average response of positive serum diluted 1:1000 was 0.231nm, the average response of negative serum diluted 1:1000 was 0.112nm, the P / N value was 2.075, and the difference was not significant.
[0162] The results showed that when the sample dilution was 1:100, the P / N value of the response was 3.844, and the distinction between positive and negative sera was the greatest. Therefore, the optimal dilution of the sample was determined to be 1:100.
[0163] (2) Critical value results
[0164] According to the conditions explored above, the serum sample dilution was 1:100, the HRP-labeled goat anti-mouse secondary antibody was diluted to 1:1000, and the DAB working solution was diluted to 1:200. According to the above operation method and conditions, 12 negative mouse sera were detected.
[0165] The results showed that the average value of the negative serum binding signal value was 0.131nm and the standard deviation (SD) was 0.018. According to the determination principle of the Cut-off value, Cut-off-P = AV + 3SD, when the binding signal value is greater than 0.186nm, the test sample is positive; Cut-off-N = AV + 2SD, when the binding signal is less than 0.168nm, the test sample is negative; when the binding signal of the test sample is between 0.168-0.186nm, it is determined to be a suspected false positive (Table 10).
[0166] Table 10 Critical value results
[0167]
[0168] In this study, the biotinylated protein of Toxoplasma GRA1 was used as the diagnostic antigen for detection and combined with a streptavidin sensor (SA) to prepare a sensor for detection, and then connected to Toxoplasma chronic infection-specific antibodies. Based on the binding of Toxoplasma-specific antibodies to HRP-labeled secondary antibodies, HRP oxidized metal chelator DAB was connected to form a precipitate and bind to the sensor surface to achieve signal amplification, thereby realizing the detection of Toxoplasma-specific antibodies in serum samples. In this experiment, serum was diluted to 100 times, HRP-labeled secondary antibodies were diluted to 1000 times, and DAB was diluted to 200 times. A single test did not exceed 20 minutes to detect Toxoplasma-specific antibodies. BLI can monitor the signal dynamics of samples in real time, and the operation difficulty coefficient is low. There is no complicated detection process, which can avoid errors caused by the operator's operating technology.
[0169] Although the present invention has been described in detail above by general description and specific embodiments, it is obvious to those skilled in the art that some modifications or improvements can be made to the present invention. Therefore, these modifications or improvements made without departing from the spirit of the present invention all belong to the scope of protection claimed by the present invention.
[0170] Sequence Listing
[0171]
[0172]
[0173]
Claims
1. A method for preparing a biotinylated GRA1 recombinant protein, characterized in that: The steps include: (1) constructing a GRA1 recombinant protein, wherein the GRA1 recombinant protein has an amino acid sequence as shown in SEQ ID NO: 1; (2) The GRA1 recombinant protein is biotinylated in the presence of BirA, and dialyzed to obtain the biotinylated GRA1 recombinant protein.
2. The method for preparing the biotinylated GRA1 recombinant protein according to claim 1, characterized in that: The construction of the GRA1 recombinant protein specifically comprises: (1-1) extracting RNA of Toxoplasma gondii RH strain and reversely transcribing it into cDNA; (1-2) using cDNA as a template to amplify the GRA1 gene, recovering and purifying the PCR product; (1-3) The purified PCR product was connected to the pET-His-MCS-Avi vector through the NdeⅠ and NotⅠ restriction sites, transformed into E. coli competent cells, and single colonies with successful cloning were picked out by ampicillin resistance, and the recombinant plasmid was extracted and named pET-His-MCS-Avi-GRA1; (1-4) Expression and purification of GRA1 recombinant protein The recombinant plasmid pET-His-MCS-Avi-GRA1 was transformed into Escherichia coli competent cells BL21 (DE3) and induced to express in LB culture medium containing ampicillin and IPTG. The bacteria were collected by centrifugation, ultrasonically disrupted, and the supernatant was separated and precipitated. The target protein was purified by Ni-NTA column and identified by SDS-PAGE and Western blot.
3. The method for preparing the biotinylated GRA1 recombinant protein according to claim 2, characterized in that: In step (1-2), The primers for amplifying the GRA1 gene include a forward primer and a reverse primer, the forward primer has a nucleotide sequence as shown in SEQ ID NO:2, and the reverse primer has a nucleotide sequence as shown in SEQ ID NO:
3.
4. The method for preparing the biotinylated GRA1 recombinant protein according to claim 2, characterized in that: In step (1-4), The induction expression conditions are: temperature 16° C., rotation speed 220 rpm, time 16 h, ampicillin concentration 100 mg / mL, IPTG concentration 0.1 mM.
5. The method for preparing the biotinylated GRA1 recombinant protein according to claim 1, characterized in that: In step (2), The biotinylation labeling reaction system is: Biotin Ligase Buffer A 10X, Biotin Ligase Buffer B 10X, BirA 100X, GRA1 recombinant protein, ddH2O, and the reaction conditions are: 30°C, 1h; The dialysis conditions are as follows: using phosphate buffer with pH=7.0 as the dialysis fluid, 2 L of dialysis fluid each time, 4° C., dialysis for 1 hour, and 3 dialysis times in total.
6. A biotinylated GRA1 recombinant protein, characterized in that: The method is prepared by the method according to any one of claims 1 to 5.
7. Use of the biotinylated GRA1 recombinant protein according to claim 6 in the detection of Toxoplasma gondii-specific antibodies in serum samples.
8. A BLI detection method for recognizing mouse positive serum based on the biotinylated GRA1 recombinant protein as claimed in claim 6, characterized in that: The following steps are involved: (1) Sensor curing: After pre-wetting the streptavidin sensor in PBS buffer for 60 seconds, immerse it in a biotinylated GRA1 recombinant protein solution diluted in PBS and incubate it at 30°C for 300 seconds. Meanwhile, record the real-time binding signal on the sensor surface. When the signal reaches saturation, terminate the binding and the sensor is cured. Store it at 4°C for future use. (2) Baseline 1: Immerse the cured sensor in serum dilution and equilibrate at 30 °C for 120 s; (3) Loading 1: Immerse the equilibrated sensor in the serum sample to be tested diluted with serum diluent and incubate at 30°C for 300 s; (4) Wash: Immerse the serum-bound sensor in serum diluent and incubate at 30°C for 60 seconds to wash away nonspecifically bound serum; (5) Loading 2: Immerse the washed sensor in HRP-labeled goat anti-mouse secondary antibody diluted in serum diluent and incubate at 30°C for 180s; (6) Wash: Immerse the sensor bound to the secondary antibody in serum dilution solution and incubate at 30°C for 60 seconds to wash the non-specifically bound secondary antibody; (7) Association: The washed sensor was immersed in DAB diluted with serum diluent and incubated at 30°C for 180s to undergo a signal amplification reaction and obtain a binding signal value. When the binding signal value was greater than 0.186nm, the sample was positive; when the binding signal value was less than 0.168nm, the sample was negative; when the binding signal value was between 0.168-0.186nm, it was determined to be a suspected false positive; (8) Dissociation: Immerse the sensor in serum dilution to terminate the signal emission reaction.
9. The BLI detection method according to claim 8, characterized in that: The serum diluent is PBS+0.02% Tween+0.1% BSA; The dilution ratio of serum samples was 1:100; The dilution ratio of HRP-labeled goat anti-mouse secondary antibody was 1:1000; The dilution ratio of DAB was 1:200.
Citation Information
Cited By
Protein visual expression method and application thereof
CN122189048A
